SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Code grade specified by pathologist. If no grade specified, code 9
M3 Module 5: PH10
Acute myeloid leukemia with 11q23 (MLL) abnormalities
Acute myeloid leukemia, 11q23 abnormalities
Acute myeloid leukemia, MLL
Note: 11q23 abnormalities don't always correlate with MLL gene rearrangement
AML with 11q23 abnormalities is usually associated with monocytic features. More common in children. Two subgroups of patients exhibit 11q23: 1) AML in infants and 2) therapy-related leukemia usually occurring after treatment with DNA topoisomerase II inhibitors
Patients may present with DIC and extramedullary monocytic sarcomas and/or tissue infiltration (gingiva, skin).
Translocations involving chromosome band 11q23 occur frequently in both AML and ALL; at least 30 different partner chromosomes are involved in recurring reciprocal 11q23 translocations, suggesting that the 11q23 breakpoint region may contain genomically unstable sequences that lead to chromosomal recombination events.
The provisional diagnoses may include AML, AML without maturation, ALL, and AML with maturation. The patients with ALL have a low percentage of MPO-positive blasts while the AML with maturation has a higher percentage of MPO-positive blasts. The patients usually present with BM failure with anemia, thrombocytopenia, and neutropenia.